Advertisement

Journal of Neuro-Oncology

, Volume 143, Issue 1, pp 101–106 | Cite as

Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes

  • Kayleen Bailey
  • Neeta Pandit-Taskar
  • John L. Humm
  • Pat Zanzonico
  • Stephen Gilheeney
  • Nai-Kong V. Cheung
  • Kim KramerEmail author
Clinical Study

Abstract

Purpose

We explored the use of intraventricular 131I-Omburtamab targeting B7-H3 in patients with ETMR.

Methods

Patients were enrolled in an IRB approved, phase 1, 3 + 3 dose escalation trial. Patients with CNS disease expressing the antibody target antigen B7-H3 were eligible. We report on a cohort of three patients with ETMR who were enrolled on the study. Three symptomatic children (ages 14 months, 3 and 3.5 years) had large parietal masses confirmed to be B7-H3-reactive ETMR. Patients received 2 mCi 131I-Omburtamab as a tracer followed by one or two therapeutic 131I-Omburtamab injections. Dosimetry was based on serial CSF, blood samplings and region of interest (ROI) on nuclear scans. Brain and spine MRIs and CSF cytology were done at baseline, 5 weeks after 131I-Omburtamab, and approximately every 3 months thereafter. Acute toxicities and survival were noted.

Results

Patients received surgery, focal radiation, and high dose chemotherapy. Patients 1 and 2 received 131I-Omburtamab (80 and 53 mCi, respectively). Patient 3 had a local recurrence prior to 131I-Omburtamab treated with surgery, external beam radiation, chemotherapy, then 131I-Omburtamab (36 mCi). 131I-Omburtamab was well-tolerated. Mean dose delivered by 131I-Omburtamab was 68.4 cGy/mCi to CSF and 1.95 cGy/mCi to blood. Mean ROI doses were 230.4 (ventricular) and 58.2 (spinal) cGy/mCi. Patients 1 and 2 remain in remission 6.8 years and 2.3 years after diagnosis, respectively; patient 3 died of progressive disease 7 months after therapy (2 years after diagnosis).

Conclusions

131I-Omburtamab appears safe with favorable dosimetry therapeutic index. When used as consolidation following surgery and chemoradiation therapy, 131I-Omburtamab may have therapeutic benefit for patients with ETMR.

Keywords

Embryonal tumor with multilayered rosettes ETMR 131I-Omburtamab 131I-8H9 Radioimmunotherapy 

Notes

Acknowledgements

We thank Mr. Joseph Olechnowicz for editorial assistance, Dr Serge Lyashchenko, HiJin Park, Jiong Wu for radiochemistry assistance. We are grateful to our patients and families for allowing us to participate in their clinical care. The authors acknowledge support from the NIH Cancer Center Support Grant P30 CA008748.

Compliance with ethical standards

Conflict of interest

Dr. N.K. Cheung reports: receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc., holding ownership interest/equity in Y-Mabs Therapeutics Inc., holding ownership interest/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor and owner of issued patents licensed by MSK to Ymabs Therapeutics, Biotec pharmacon, and Abpro-labs. NKC is a consultant/advisory board member for Abpro-Labs and Eureka Therapeutics. Dr. Pat Zanzonico is the inventor on a patent pending for systems and methods for determining optimum patient-specific antibody dose for tumor targeting. Dr. Kim Kramer is a consultant to Ymabs Therapeutics Inc. 8H9 is currently licensed to Ymabs Therapeutics. Data in this report was acquired prior to their sponsorship of this study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving animal rights

There were no animals involved.

References

  1. 1.
    Niguez BF, Martínez-Lage JF, Almagro MJ et al (2010) Embryonal tumor with abundant neuropil and true rosettes (ETANTR): a new distinctive variety of pediatric PNET: a case-based update. Childs Nerv Syst 26:1003–1008CrossRefGoogle Scholar
  2. 2.
    Spence T, Sin-Chan P, Picard D et al (2014) CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 128:291–303CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mozes P, Hauser P, Hortobágyi T et al (2016) Evaluation of the good tumor response of embryonal tumor with abundant neuropil and true rosettes (ETANTR). J Neurooncol 126:99–105CrossRefPubMedGoogle Scholar
  4. 4.
    Eberhart CG, Brat DJ, Cohen KJ, Burger PC (2000) Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol 3:346–352CrossRefPubMedGoogle Scholar
  5. 5.
    Manjila S, Ray A, Hu Y, Cai DX, Cohen ML, Cohen AR (2011) Embryonal tumors with abundant neuropil and true rosettes: 2 illustrative cases and a review of the literature. Neurosurg Focus 30:E2CrossRefPubMedGoogle Scholar
  6. 6.
    Horwitz M, Dufour C, Leblond P et al (2016) Embryonal tumors with multilayered rosettes in children: the SFCE experience. Childs Nerv Syst 32:299–305CrossRefPubMedGoogle Scholar
  7. 7.
    Jaramillo S, Grosshans DR, Philip N et al (2019) Radiation for ETMR: literature review and case series of patients treated with proton therapy. Clin Transl Radiat Oncol 15:31–37CrossRefPubMedGoogle Scholar
  8. 8.
    Padovani L, André N, Constine LS, Muracciole X (2012) Neurocognitive function after radiotherapy for paediatric brain tumours. Nat Rev Neurol 8:578–588CrossRefPubMedGoogle Scholar
  9. 9.
    Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61:4048–4054PubMedGoogle Scholar
  10. 10.
    Ahmed M, Cheng M, Zhao Q et al (2015) Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J Biol Chem 290:30018–30029CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Souweidane MM, Kramer K, Pandit-Taskar N et al (2018) Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol 19:1040–1050CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Miraldi FD, Nelson AD, Kraly C et al (1986) Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161:413–418CrossRefPubMedGoogle Scholar
  13. 13.
    Kramer K, Humm JL, Souweidane MM et al (2007) Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25:5465–5470CrossRefPubMedGoogle Scholar
  14. 14.
    Chi SN, Zimmerman MA, Yao X et al (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385–389CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kramer K, Pandit-Taskar N, Zanzonico P et al (2015) Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. J Neurooncol 123:245–249CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Radiology (Molecular Imaging and Therapy Service)Memorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Medical PhysicsMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations